Thrombocytopenia is generally of central origin in MDS, but can be due to peripheral platelet destruction in some cases. We studied platelet lifespan in 61 MDS cases with platelets Ͻ70 000/mm 3 and marrow blasts Ͻ10%. Nine of them (15%) had a major platelet lifespan reduction (Ͻ3.5 days), and were considered for splenectomy. Three of them were not splenectomized due to rapid death, patient refusal and older age plus liver predominance of platelet sequestration, respectively. The remaining six patients (two females and four males, median age 50 years, range 32 to 65) were splenectomized 3 to 21 months after diagnosis. Before splenectomy, five of them had RA and one had CMML. Platelets counts ranged from 5000 to 30 000/mm 3 and did not durably respond to other treatments. Three of the patients has a relapse of platelet counts, concomitantly required platelet transfusion due to recurrent blending, whereas three had anemia (two required erythrocyte transfusion) and four had neutropenia. Three months after surgery, platelet counts ranged from 55 000 to 160 000/mm 3 (Ͼ100 000/mm 3 in four cases), no patient required platelet or erythrocyte transfusion, but there was no effect on neutrophil counts. Three patients had a relapse of platelet counts, concomitant with progression to AML in two of them, whereas the third relapsing case achieved normal platelet counts with further danazol. One patient died with normal platelet counts 12 months after splenectomy (from sepsis, probably related to neutropenia rather than splenectomy). Two patients remained with normal platelet counts 10 and 52 months after surgery. Our findings suggest that the mechanism of thrombocytopenia should be studied more often in 'low risk' MDS (ie with low bone marrow blast counts) with thrombocytopenia, as about 15% of them appear to have peripheral platelet destruction. Some of those patients may benefit from splenectomy. Leukemia (2001) 15, 950-953. 
Introduction
Myelodysplastic syndromes (MDS) are clonal stem cell disorders characterized by ineffective hematopoiesis leading to blood cytopenias, especially thrombocytopenia, which can be life-threatening. 1, 2 Thrombocytopenia, in MDS, is usually mainly of central origin, associated with normal platelet lifespan. Peripheral immune destruction of platelets has, however, also been observed in some cases of MDS, and improvement of platelet counts with drugs used in autoimmune thrombocytopenic purpura (AITP) (including steroids, vinca alkaloids, high-dose immunoglobulins and androgens) has been reported in some of those patients. [3] [4] [5] [6] [7] In a previous prospective study, we found reduced platelet lifespan in five of 30 MDS cases with marrow blasts below 10% and platelets below 70 000/mm platelet autoantibodies (detected by the MAIPA test), but their presence was not correlated with platelet lifespan. 7 Because splenectomy remains the mainstay in the treatment of chronic AITP, 8 we evaluated the efficacy of splenectomy in six MDS patients with life-threatening thrombocytopenia and reduced platelet lifespan.
Patients and methods

Patients
Between 1994 and 1999, we studied platelet lifespan with 111 Indium labelled platelets in 61 cases of MDS (classified according to FAB criteria) with a platelet count Ͻ70 000/mm 3 and Ͻ10% marrow blasts ('low risk' MDS), after informed consent. Patients were all retrospectively classified using the international prognostic scoring system (IPSS). 9 Platelet lifespan was reduced (Ͻ6 days) in 15 of those 61 cases, and greatly reduced (Ͻ3.5 days) in nine of them, in whom splenectomy was considered, and who form the basis of the present study.
Methods
Specific platelet autoantibodies were detected by the MAIPA technique, as previously described. 10 Measurement of platelet lifespan and study of the sequestration site of 111 In labelled platelets was performed as in previous studies. 8 External counting, using a three-directional scintillation counter (2 × 2Љ Na I crystals) was performed simultaneously on spleen, liver and precordium areas at 15 min, 1 h, 3 h and daily thereafter. The following parameters were determined: spleen sequestration index (S) = spleen activity at t spleen activity at 15 min Ͳ precordium activity at t precordium activity at 15 min liver sequestration index (L) = liver activity at t liver activity at 15 min Ͳ precordium activity at t precordium activity at 15 min and S/L ratio. The sequestration was noted as predominantly splenic if S/L was Ͼ1, and predominantly hepatic if S/L was Ͻ1.
Results
Platelet lifespan
Platelet lifespan was normal (у6 days) in 46 patients, and reduced in the remaining 15 patients (24%). Among the latter, six had moderate in platelet lifespan reduction (3.5 to 6 days), and nine (15%) had major reduction (Ͻ3.5 days). In those nine patients, the preferential site of labelled platelets was the spleen (S/L Ͼ1) in six cases, the liver S/L Ͻ1 in two cases, and both organs (S/L Ϸ 1, without predominance of one organ over the other) in two cases.
Characteristics of the nine patients with major platelet lifespan reduction
Those patients included six females and three males, with a median age of 59 years (range 32 to 74). Interval from diagnosis to platelet lifespan study ranged from 3 to 21 months (median 12). At the time of platelet lifespan study, platelets ranged from 6000 to 60 000/mm 3 (median 20 000). Seven of the nine patients had refractory anemia (RA), one had refractory anemia with excess of blasts (RAEB) and one had chronic myelomonocytic leukemia (CMML). One of the patients (patient No. 1 in Table 1 ) initially had RAEB-T, treated with intensive chemotherapy, and achieved partial response, with 'reversal' to RA with isolated thrombocytopenia. Overall, two of the nine patients had isolated thrombocytopenia and seven also had neutropenia and/or anemia. All patients had previously received some form of treatment for their thrombocytopenia, including steroids in five cases, interleukin 3 in three cases, high-dose intravenous immunoglobulins in two cases, with no effect; danazol (600 to 800 mg/day for at least 3 months) in seven cases, to which four responded transiently. Platelet autoantibodies, using the MAIPA test, were found in three of the six tested patients.
Six of the nine patients were splenectomized ( Table 1) . The remaining three patients were not splenectomized: one of them rapidly died from CNS bleeding. One refused splenectomy. She was 74 years old, with RAEB, normal karyotype and 30 000 platelets/mm 3 . Treatment with danazol was started and platelets were at 70 000/mm 3 1 year later, when the patient was lost to follow-up. The last patient was 73 years old with RA, isolated del5q and 30 000/mm 3 platelets. Due to age and liver predominance of the sequestration of labelled platelets, splenectomy was eventually not performed. The patient, who did not respond to steroids and danazol, died 2 years later, from CNS bleeding. The patient who refused splenectomy also had liver predominance, whereas the patient who rapidly died had splenic predominance of sequestration of labelled platelets.
Results of splenectomy
Hematological characteristics of the six patients who were splenectomized are shown in Table 1 . Before splenectomy, patients 1 and 2 had isolated thrombocytopenia, whereas patients 4, 5 and 6 also had anemia (patients 4 and 6 were dependent on erythrocyte transfusions) and patients 3 and 4 also had neutropenia. No patient had signs of hemolysis, and the direct antiglobulin test was negative in all cases. Three patients (1, 4 and 6) required platelet transfusions due to severe bleeding. Two patients (4 and 6) had moderate palpable splenomegaly whereas the spleen was of normal size (including by ultrasound exploration) in the four other cases. Cytogenetic analysis was normal in four cases and showed isolated del 20q in two cases. IPPSS score was 0 in two patients, and 0.5 in four patients. Platelet counts ranged from 5000 to 30 000/mm 3 before splenectomy, and from 55 000 to Leukemia 160 000/mm 3 3 months after splenectomy (greater than 100 000/mm 3 , ie complete response, in four of the six cases, and partial response, ie platelets at least doubled, and Ͼ500 000/mm 3 , in the two remaining cases) and all patients became platelet transfusion-independent. All patients received pneumococcal vaccine prior to surgery, and received post operative daily penicillin. No postoperative complications were seen. Anemia was corrected by splenectomy in two of the three cases with anemia before surgery (the two patients that were dependent on erythrocyte transfusion), but no effect on neutrophils was seen.
With a median follow-up of 12 months (range 10-52), three patients (1, 4 and 6) had a relapse of their thrombocytopenia, after 9, 7 and 4 months, respectively. In patients 4 and 6, both partial responders to splenectomy, relapse was rapidly followed by progression to AML and subsequent death. After relapse, patient No. 1 was retreated by danazol, with complete response, and remained with platelet counts at about 160 000/mm 3 , 5 months later. In the remaining three patients (2, 3 and 5), platelets remained stable after 10, 52 and 12 months, respectively. One of them (No. 5) died from infection (progressively extending pneumonia) after 12 months with normal platelets counts (he had neutrophil counts below Ͻ1000/mm 3 ). Platelets remained between 100 and 150 000/mm 3 in patient No. 2, and were normal in patient No. 3, 52 and 10 months, respectively, after surgery.
After splenectomy two patients developed immune disorders, including Sjö gren's syndrome (one case) and vasculitis (one case).
Discussion
In this study, 15 of 61 patients with 'low risk' MDS and thrombocytopenia had peripheral immune destruction of platelets with reduced platelet lifespan, confirming our preliminary findings. 7 Nine of those 15 patients had a major reduction (Ͻ3.5 days) of platelet lifespan. They had predominantly RA (seven cases), but thrombocytopenia was the only cytopenia in only two cases ('refractory thrombocytopenia'). Specific platelet autoantibodies were found in three of the six cases evaluated, confirming the absence of close correlation between reduced platelet lifespan and platelet antibodies in MDS we had previously observed. 7 Platelet autoantibodies have been found by other groups in 60 to 80% of MDS cases, but often using nonspecific tests, that could not identify specific platelet autoantibodies. 3, 5 In addition, no platelet lifespan study was made in those reports.
A few cases of response of thrombocytopenia of MDS to steroids or intravenous immunoglobulins have been reported, 2,11 but it was not determined if those patients had peripheral immune destruction of platelets, and those drugs were ineffective in our patients. Likewise, androgens, mainly danazol, can improve thrombocytopenia in 30 to 40% of MDS cases, but this effect was not restricted to cases of MDS with reduced platelet lifespan in our experience and in other studies. [4] [5] [6] [7] In the present study, four of the seven MDS cases with greatly reduced platelet lifespan treated with danazol responded transiently to this drug, in agreement with our overall response rate of 30 to 40% in previous studies. 6, 7 Very few cases of splenectomy in MDS have been reported. A few anecdotal cases of MDS where splenectomy was performed for splenomegaly or cytopenias were reported, generally without response.
11,12
The mechanism of cytopenias, especially thrombocytopenia, had not been studied. Recently, Kraus et al, 13 retrospectively analyzing surgical pathology files at their institution, found nine cases of splenectomy performed in MDS, including RA in six cases, CMML in two cases, and unclassified MDS in one case. Age ranged from 65 to 77 years. The indication for splenectomy was thrombocytopenia in five cases, pancytopenia in three cases, and trauma in one case. After splenectomy, three patients had sustained improvement in blood counts, two had transient improvement, three had no response and the last patient had early postoperative death. The mechanism of cytopenias (autoimmune peripheral component?) was unknown, and no platelet lifespan study had been performed. Therefore it is uncertain if patients in whom platelet counts improved had peripheral thrombocytopenia. In fact, splenectomy may also improve cytopenias of central origin, as suggested by the favorable results obtained in some cases of aplastic anemia. 14 In the present study, all six splenectomized patients had a major improvement of platelet counts after the procedure: four of them achieved platelet counts greater than 100 000/mm 3 , and the remaining two patients with platelet counts of 5000 and 15 000/mm 3 before splenectomy, achieved platelet counts greater than 50 000/mm 3 . Two of the six patients progressed to AML after a few months, with concomitant relapse of platelet counts. A report also suggested that splenectomy could have triggered progression to AML in one case of MDS, 11 and splenectomy could increase the risk of blastic transformation in agnogenic myeloid metaplasia. 15 On the other hand, in our two patients worsening of thrombocytopenia, which led to platelet exploration and splenectomy, could have been a sign of disease progression that preceded 'natural' evolution to AML. One patient also died after 12 months, from sepsis with normal platelet counts. Because of its clinical features (pneumonia of progressive evolution, rather than fulminant sepsis), it could not be determined if this infectious episode was due to post-splenectomy immune deficiency or to neutropenia. Another relapse of thrombocytopenia was seen at 9 months, but the patient responded to a new course of danazol, to which she had become refractory, and had platelet counts of 160 000/mm 3 , 5 months later. The last two patients had persistent platelet response, 10 and 52 months after surgery. Splenectomy also corrected anemia in two of the three anemic patients, who previously required erythrocyte transfusions.
Our results confirm that in about 15% of MDS with marrow blasts Ͻ10%, thrombocytopenia has a peripheral component. Thrombocytopenia is usually severe in those cases, and some of those patients may benefit from splenectomy for platelet counts, but also in some cases for hemoglobin levels. Our results will, of course, have to be confirmed with larger numbers of cases. They also suggest that 'low risk' MDS (ie with low or low-intermediate IPSS score) with severe thrombocytopenia could benefit from more systematic analysis of the mechanism of thrombocytopenia.
